

UCL-Advanced Diagnostics

2015/16 Test & Service List



2015/16 TEST & SERVICE LIST

Haematoxylin & Eosin

H&E

H&E per slide

Routine Immunohistochemistry

Immunohistochemical demonstration of an antigen in a paraffin section & cytopins using routine antibodies with polymer-HRP DAB visualisation*

Patient Test

Positive Control

Negative Control

*Red immunohistochemical test is available upon request using polymer-AP Fast Red visualisation

Double-stain Immunohistochemistry Assays

Immunohistochemical demonstration of antigens in a paraffin section & cytopins using routine antibodies with polymer-HRP DAB & AP Fast Red visualisation

Patient Test

Positive Control

Negative Control

Digital Pathology

High quality digital remote case review over the web, using a secure, high speed, managed browser

High Resolution Brightfield Image Scan per slide

Specialist Immunohistochemical Assays

Immunohistochemical demonstration of an antigen in paraffin section & cytopins using companion diagnostic kits/specialist assays

CD117 (c-kit) Test
 CD117 (c-kit) Control
 Dako c-kit Polyclonal Rabbit Anti-human

p16 Test
 p16 Control
 Roche MTM CINtec® p16^{INK4a}

BREAST & GASTRIC CANCER

HER2 IHC Test including interpretation⁺

HER2 IHC Test

HER2 IHC Control
 Roche Tissue Diagnostics Pathway HER2 (4B5) Assay

⁺Specialist interpretative assays include an H&E-stained section

EGFR IHC Test
 EGFR IHC Control
 Roche Tissue Diagnostics Confirm EGFR (C36) IHC Assay

ER + PR + HER2 IHC including interpretation⁺
 Leica ER (6F11) + PR (16) + Roche Tissue Diagnostics Pathway HER2 (4B5) IHC Assay

⁺Specialist interpretative assays include an H&E-stained section

NON-SMALL CELL LUNG CANCER

ALK IHC Test including interpretation⁺

ALK IHC Test

ALK IHC Control

Roche Tissue Diagnostics ALK (D5F3) Assay

⁺ Specialist interpretative assays include an H&E-stained section

HNPCC panel for Lynch Syndrome including interpretation
⁺MLH1 + MSH2 + MSH6 + PMS2

⁺HNPCC includes unstained spare sections or tissue rolls cut for
 Microsatellite instability (MSI) as determined by PCR if required

Specialist CISH Assays

Chromogenic in situ demonstration of target mRNA or DNA

mRNA PROBES

EBER (EBV) Test
EBER (EBV) Control

CMV Test
CMV Control

KAPPA (Plasma cells) Test
KAPPA (Plasma cells) Control

LAMBDA (Plasma cells) Test
LAMBDA (Plasma cells) Control

DNA PROBES

HPV – High Risk Test (Subtypes 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 66)
HPV – High Risk Control
HPV – Low Risk Test (Subtypes 6, 11)
HPV – Low Risk Control
HPV – DNA Positive Control

New HPV Assay including additional high risk subtypes using Roche targeted Inform HPV ISH probes (Blue Chromogen/NFR Counterstain)

Brightfield Dual Hapten Silver in situ demonstration of target DNA for Gene Amplification Analysis

BREAST & GASTRIC CANCER

HER2 (ERBB2)/CEP17 DDISH including interpretation[†]
Roche Tissue Diagnostics Inform DDISH HER2/CEP17 Assay (Dual Probe/Dual Hapten Silver Method)

[†]Please note following interpretation stained DDISH slides are archived on site at UCL-AD

In-Situ Hybridisation Assays - Oncology (Amplification FISH)

Fluorescent in situ demonstration of target DNA for Gene Amplification

BREAST & GASTRIC CANCER

HER2(ERBB2)/CEP17 FISH including interpretation (by prior arrangement)
Abbott Molecular PathVysion™ HER2/CEP17 DNA Probe Kit

LUNG & GASTRIC CANCER

MET/CEP7 including interpretation
Zytovision Zytolight SPEC MET/CEN7 DNA Probe Kit

BREAST & LUNG & GI CANCER

FGFR1 (8p11)/SE8 including interpretation
Kreatech Diagnostics DNA Probe

NEW TEST

BREAST, LUNG & GI CANCER

FGFR2 (10q23)/SE10 including interpretation
Zytovision Zytolight SPEC FGFR2/CEN10 DNA Probe Kit

NEW TEST

In-Situ Hybridisation Assays - Oncology (Translocation/Rearrangement FISH)

Non-Small Cell Lung Cancer
ALK (2p23) including interpretation
Abbott Molecular ALK FISH Probe for NSCLC

ROS1 (6q22) including interpretation
Kreatech Diagnostics ROS1 (6q22) Break Apart probe

RET (10q11) including interpretation
Kreatech Diagnostics RET (10q11) Break Apart probe

NEW TEST

In-Situ Hybridisation Assays - Haematopathology (Translocation FISH)

Fluorescent in situ demonstration of target DNA for Translocation Analysis using break-apart & fusion translocation probes

BCL2 including interpretation
Abbott Molecular BCL2 FISH Probe

BCL6 including interpretation
Abbott Molecular BCL6 FISH Probe

CCND1 including interpretation
Abbott Molecular CCND1 FISH Probe

MALT1 including interpretation
Abbott Molecular MALT1 FISH Probe

MYC including interpretation[†]
Abbott Molecular MYC FISH Probe

[†]Please note that if the break-apart probe proves inconclusive, we will perform a second FISH test using the MYC fusion probe (see below)

MYC/IGH Dual Fusion including interpretation
Abbott Molecular MYC/IGH/CEP8 Dual-Fusion Triple Colour FISH Probe

IGH including interpretation
Abbott Molecular IGH FISH Probe

In-Situ Hybridisation Assays - Diagnostic Aids (Aneuploidy FISH)

Fluorescent in situ detection of aneuploidy in Bladder Cancer

BLADDER CANCER SCREEN (URINE CYTOLOGY)
CEP3, CEP7, CEP17 & P16 (9p21) including interpretation
Abbott Molecular UroVysion™ DNA Probe Kit

Fluorescent in situ detection of aneuploidy in Melanoma

MELANOMA – DIAGNOSTIC AID FOR BORDERLINE LESIONS
MYB, CCND1, RREB1 & CEP6 including interpretation
Abbott Molecular Melanoma DNA Probe Kit

Somatic Mutation Profiling

Mutation analysis by NGS

22-gene panel mutation analysis

MGP-1:

Includes interpretive comments for genes/mutations currently associated with NICE approved therapies. ABL1, ALK, BRAF, CTNNB1, DDR2, EGFR, ERBB2, ERBB4, FBXW7, FGFR1, FGFR2, FGFR3, KRAS, MAP2K1, MET, NOTCH1, NRAS, PIK3CA, PTEN, SMAD4, STK11, TP53.

50-gene panel mutation analysis

NEW TEST

Ion AmpliSeq™ Cancer Hotspot Panel v2:

Includes interpretive comments for genes/mutations currently associated with NICE approved therapies. ABL1, AKT1, ALK, APC, ATM, BRAF, CDH1, CDKN2A, CSF1, RCTN, NB1, EGFR, ERBB2, ERBB4, EZH2, FBXW7, FGFR1, FGFR2, FGFR3, FLT3, GNA11, GNAQ, GNAS, HNF1A, HRAS, IDH1, IDH2, JAK2, JAK3, KDR, KIT, KRAS, MET, MLH1, MPL, NOTCH1, NPM1, NRAS, PDGFRA, PIK3CA, PTEN, PTPN11, RB1, RET, SMAD4, SMARCB1, SMO, SRC, STK11, TP53, VHL.

Available May/June 2015. Please confirm availability: molecular@uclad.com

Mutation analysis by Real-time PCR

BRAF mutation analysis *including interpretation* (single gene assay)

Lymphoma Clonality Assays

PCR Analysis

B-cell clonality
IgH, IGK

T-cell clonality
TCR GAMMA, TCR BETA and TCR DELTA

B-cell and T-cell clonality
IgH, IGK, TCR GAMMA, TCR BETA and TCR DELTA

Our enhanced assay scheme complies with Euroclonality consortium

recommendations References:

- 1) *A practical strategy for the routine use of BIOMED-2 PCR assays for detection of B- and T-cell clonality in diagnostic haematopathology. Liu-H et al. BJH 2007,138:31-43*
- 2) *EuroClonality/BIOMED-2 guidelines for interpretation and reporting of Ig/TCR clonality testing in suspected lymphoproliferations. Langerak-AW et al. Leukemia 2012, 26: 2159–2171*

Contact Details

<i>Slide-based Testing (IHC, ISH)</i>	<i>Mutational Profiling</i>
<p>Mr. David Allen, MSc. Lead BMS/Clinical Services Manager Tel: 020 7679 6912 Email: david.allen@ucl.ac.uk</p>	<p>Dr Phil Bennett, PhD. Principal Clinical Scientist Tel: 020 7679 9338 Email: p.bennett@ucl.ac.uk</p>
<p>Dr. Naomi Guppy, MSc., PhD. Senior BMS/Research Services Manager Tel: 020 7679 6913 Email: n.guppy@ucl.ac.uk</p>	<p>Mr. Ben Poskitt, MSc. Deputy Clinical Services Manager Tel: 020 7679 9338 Email: b.poskitt@ucl.ac.uk</p>

Payment Terms

Payment using BACS is preferred*, our details are as follows:

O V University College London
 " Barclays, Bloomsbury and Tottenham Court Road
 Branch, 6-17 Tottenham court Road, W1T 1BH.
 ° V 40178691
 O # 20-10-53

*Please reference invoice number

Remittance to : creditcontrol@ucl.ac.uk

Simon Mackie /Agne Milford

UCL-Advanced Diagnostics
 1st Floor, Rockefeller Building
 21 University Street
 London
 WC1E 6JJ
 Tel No: 020 7679 6913
 Email: simon.mackie@ucl.ac.uk & a.milford@ucl.ac.uk

An indication of charge is returned with all stained slides.
 Payment will be due 30 days from the date of our invoice.

For private healthcare requests which are to be billed via personal patient insurance, requests *must* be accompanied with complete details of the patient **Insurance Policy Provider** and **Insurance Policy Number**. If an alternative method of payment of invoices is preferred, or for any further information please contact **Simon Mackie** or **Agne Milford**.

UCL-Advanced Diagnostics

Rockefeller Building

21 University Street

London

WC1E 6JJ

Tel: 02076796039

Fax: 02076796275

Email: info@uclad.com

Web: www.uclad.com



www.uclad.com